Fortress Biotech Q2 FY26 turns to net loss of $2.5 million; revenue rises 14% to $18.7 million

Reuters2026/08/13 20:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fortress Biotech Q2 2026 revenue rose 14% to $18.7 million versus Q2 2025, with $17.8 million from marketed dermatology products.
Net loss attributable to common stockholders turned to $2.5 million, or $0.08 per share, from net income of $13.4 million a year earlier.
R&D expense fell to $0.8 million from $8.1 million, while SG&A dropped to $20.8 million from $38.8 million.
Cash and cash equivalents climbed to $196.6 million at June 30 from $79.4 million at Dec. 31, 2025.
Management cited momentum across partnered programs, including Crystalys’ $130 million Series B for dotinurad and royalties from ZYCUBO and UNLOXCYT launches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fortress Biotech Q2 FY26 turns to net loss of $2.5 million; revenue rises 14% to $18.7 million

You may also like

Crypto prices